HAILE_PAMELA CV 12.15.14

Pamela A. Haile (Cleary)
GlaxoSmithKline
1250 Collegeville Road
UP1205
Collegeville, PA 19426
(610) 917-6517
pamela.a.haile@gsk.com
Education
Doctor of Philosophy in Chemistry, University of North Carolina-Chapel Hill, Department of
Chemistry; December 2003. Research advisor: Professor Michael T. Crimmins.
B.A. magna cum laude with distinction in chemistry, Hendrix College, Conway, AR; May 1998.
Professional Experience
Senior Scientific Investigator, GlaxoSmithKline, Immuno-Inflammation Therapeutic Area; November
2014-present.
· Serve as a member of the Medical Chemistry Leadership Team.
· Lead chemical series for immuno-inflammation programs.
· Investigation of new targets.
Investigator, GlaxoSmithKline, Immuno-Inflammation Therapeutic Area; April 2010-November 2014.
· Served as a member of the Medical Chemistry Leadership Team
· Led chemical series for immuno-inflammation program. Key responsibilities included: critical
analysis of biological and pharmacokinetic data to choose and resource chemical targets and
communication of results to broader audiences. This work culminated in a candidate selection
from this series in June 2011and two back-up molecules in 2014.
· Managed team of 6 chemists while leading the quinoline series; Directly manage 2 associate
chemists and purification laboratory shared by two departments
· Filed multiple patents around the quinoline and quinazoline series and assembled key scientific
documents required for candidate selection
· Oversaw scale-up of compounds for safety assessment and coordinated CD1 and CD2 campaigns
with the exploratory developmental sciences group
· Organized and led compound biweekly progression meetings for each chemical series within a
program; assessed compounds for further progression and coordinated the teams requests with
cross matrix partners
· Hosted external consultant on targeted drug delivery to the colon for Crohn’s Disease / Ulcerative
Colitis and led internal discussion on the topic in the format of Senior Staff Meetings
· Participated in 2013 Innovation Retreat with a specific focus on targeted drug delivery
· Served as a participant in a 6-membered committee formed as part of a Chemistry Council
initiative to formulate a proposal to be put forth to the R&D Leadership Team on early talent
recruitment
· Organized departmental volunteer “Orange Day” for 50+ volunteers in 2010 and 2011
· Served as UP Lead Day panelist for a discussion on translating strategy into action
Principal Scientist, GlaxoSmithKline, Immuno-Inflammation Therapeutic Area; July 2008-April 2010.
· Led a quinoline based series for the RIP2K program

· Progressed 2 compounds through safety assessment studies
· Managed 1 associate chemist and purification laboratory
Principal Scientist, GlaxoSmithKline, Metabolic Pathways Medicinal Chemistry; January 2006-July
2008.
· Synthesized potential drug candidates for a cardiovascular program by exploring new organic
chemistry routes
· Coordinated studies with biologists and saw that chemistry team met deadlines
· Formulated target compound lists based on existing SAR, one of which became the selected drug.
candidate for the project in December 2007
· Assembled safety assessment documents and patents that were critical for the project
· Managed 1 associate chemist
· Coordinated outsourcing efforts with WuXi AppTec for current program
Postdoctoral Research Associate, University of California-Irvine, Department of Chemistry; January-
2004-December 2005. Research Advisor: Professor Keith A. Woerpel.
· Discovered unprecedented rearrangement of homoallylic ethers and designed experiments to
elucidate the mechanism of the reaction
Group Coordinator, Woerpel Laboratory, University of California-Irvine, Department of Chemistry;
January 2005-December 2005.
· Supervised graduate students
· Assigned group responsibilities and saw that they were carried out
· Ordered supplies and chemicals
· Organized group meetings
· Organized and coordinated laboratory move with safety officials
Research Assistant, University of North Carolina-Chapel Hill, Department of Chemistry; 1999-2003.
Research Advisor: Professor Michael T. Crimmins.
· Completed the synthesis of the G and J rings of ladder ether brevetoxin A
· Served as laboratory coordinator: ordered laboratory supplies and chemicals and organized group
clean-ups
Teaching Assistant, University of North Carolina at Chapel Hill, Department of Chemistry; 1998-1999.
· Instructed undergraduate students in laboratory techniques and lecture material
Undergraduate Research Assistant, Hendrix College, Department of Chemistry; June 1996-August
1996, June 1997-May 1998. Research Advisor: Professor David A. Hales.
· Studied the ion-molecule chemistry of BF3 in clusters in a time of flight mass spectrometer
Undergraduate Research Assistant, University of Arkansas for Medical Sciences, January 1998 – May
1998. Research Advisor: Professor Tom E. Goodwin.
· Worked on the synthesis of radiolabeled salmeterol to be used as an internal PK standard
Undergraduate Teaching Assistant, Hendrix College, Department Chemistry; 1996-1998.
· Supervised undergraduate students in a laboratory setting
Awards & Recognition
2014 Silver Award, GlaxoSmithKline

2013 Recognized as Key Talent within the II TAU
2012 Bronze Award, GlaxoSmithKline
2011 Exceptional Science Award, GlaxoSmithKline
2011 Gold Award, GlaxoSmithKline
2000-2001 GAANN Fellow, UNC-Chapel Hill
1999-2000 Burroughs-Wellcome Fellow, UNC-Chapel Hill
1999 Synlett Award, UNC-Chapel Hill
1998-1999 Francis P. Venable Fellow, UNC-Chapel Hill
1998 Phi Beta Kappa Honors Society
1998 American Institute of Chemists Award, Hendrix College
1994-1998 Trustees’ Scholarship, Hendrix College
Memberships American Chemical Society; Organic Division of the American Chemical Society;
Medicinal Chemistry Division of the American Chemical Society; Phi Beta Kappa.
Publications
29. P. Mandal; S. B. Berger; S. Pillay; K. Moriwaki; C. Huang; H. Guo; J. D. Lich; J. Finger; V.
Kasparcova; B. Votta; M. Ouellette; B. W. King; D. Wisnoski; A. S. Lakdawala; M. P. DeMartino; L. N.
Casillas; P. A. Haile; C. A. Sehon; R. W. Marquis; J. Upton; L. P. Daley-Bauer; L. Roback; N. Ramia; C.
M. Dovey; J. E. Carette; F. K.-M. Chan; J. Bertin; P. J. Gough; E. S. Mocarski; W. J. Kaiser, “RIP3
Induces Apoptosis Independent of Pronecrotic Kinase Activity,” Molecular Cell 2014, 56, 481 – 495.
28. D. J. Rickard; C. A. Sehon; V. Kasparcova; L. A. Kallal; P. A. Haile; X. Zeng; M. N. Montoute; T.
Chordia; D. D. Poore; H. Li; Z. Wu; P. M. Eidam; J. Yu; J. G. Emory; R. W. Marquis; P. J. Gough; J.
Bertin, “Identification of selective small molecule inhibitors of the nucleotide-binding oligomerization
domain 1 (NOD1) signaling pathway,” PLoS One 2014, 9, e96737.
27. D. J. Rickard; C. A. Sehon; V. Kasparcova; L. A. Kallal; X. Zeng; M. N. Montoute; T. Chordia; D. D.
Poore; H. Li; Z. Wu; P. M. Eidam; P. A. Haile; J. Yu; J. G. Emory; R. W. Marquis; P. J. Gough; J. Bertin,
“Identification of benzimidazole diamides as selective inhibitors of the nucleotide-binding
oligomerization domain 2 (NOD2) signaling pathway,” PLoS One 2013, 8, e69619.
26. M. Bury; L. Casillas; A. Charnley; M. P. DeMartino; X. Dong; P. M. Eidam; P. A. Haile; B. Marquis;
J. Ramanjulu; J. Romano; R. R. Singhaus; A. Lakdawala; G. Wang, “Preparation of aminoquinazolines as
RIP2 kinase inhibitors,” PCT Int. Appl. (2013), WO 2013025958.
25. M. Bury; L. Casillas; A. Charnley; P. A. Haile; B. Marquis; J. Mehlmann; J. Romano; R. Singhaus;
G. Wang, “Amino-quinolines as kinase inhibitors,” PCT Int. Appl. (2012), WO 2012122011.
24. L. Casillas; A. Charnley; P. A. Haile; T. V. Hughes; B. Marquis; J. Mehlmann; M. Reilly; J.
Romano; R. Singhaus, “Quinolyl amines as kinase inhibitors,” PCT Int. Appl. (2012), WO 2012021580.
23. G. Z. Wang; P. A. Haile; T. Daniel; B. Belot; A. Viet; K. Goodman; D. Sha; S. Dowdell; N. Varga;
X. Hong; S. Chakravorty; C. Webb; C. Cornejo; A. Olzinski; R. Bernard; C. Evans; A. Emmons; J.
Briand; C.-W. Chung; R. Quek; D. Lee; P. J. Gough; C. A. Sehon, “CCR2 receptor antagonists:
Optimization of biaryl sulfonamides to increase activity in whole blood,” Bioorg. Medicinal Chem. Lett.
2011, 21, 7291-7294.
22. M. Bury, L. Casillas; A. Charnley; M. DeMartino; X. Dong; P. A. Haile; P. Harris; A. Lakdawala-
Shah; B. King; B. Marquis; J. Melhmann; J. Romano; C. A. Sehon; P. Eidam, “Amino-quinolines as
kinase inhibitors,” PCT Int. Appl. (2011), WO 20111404420.

21. L. Casillas; S. Chakravorty; P. Eidam; P. A. Haile; T. V. Hughes; A. Lakdawala-Shah; L. Leister; N.
Miller; A. Rahman; C. Sehon; G. Wang; D. Zhang, “ Preparation of pyrazolyl-substituted
pyrimidinediamine derivatives as RIP2 kinase inhibitors, “ PCT Int. Appl. (2011), WO 2011120026.
20. L. Casillas; S. Chakravorty; A. Charnely; P. Eidam; P. A. Haile; T. V. Hughes; J. Jeong; J. Kang; A.
Lakdawala-Shah; L. Leister; R. Marquis; N. Miller; D. Price; C. Sehon; G. Wang; D. Zhang, “
Preparation of indazolyl-substituted pyrimidinediamine derivatives as RIP2 kinase inhibitors, “ PCT Int.
Appl. (2011), WO 2011120025.
19. P. Eidam; P. A. Haile; T. V. Hughes; T. A. Miskowski; C. A. Sehon, “Indolinyl-, benzofuranyl-,
benzothienyl- amides as modulators of chemokine receptors,” PCT Int. Appl. (2010) WO2010093578.
18. P. A. Haile; C. A. Sehon; H. Wang, “Process for Enantioselective preparation of piperidin-1-ylmethyl
piperidin-4-yl carbinols,” PCT Int. Appl. (2010) WO2010099098.
17. M. T. Crimmins; J. M. Ellis; K. A. Emmitte; P. A. Haile; P. J. McDougall; J. D. Parrish; J. L.
Zuccarello, “Enantioselective Total Synthesis of Brevetoxin A: Unified Strategy for the B, E, G, and J
Subunits,” Chem. Eur. J. 2009, 15, 9223-9234.
16. L. E. Bourque; P. A. Haile; K. A. Woerpel, “Silylene-Mediated Ring Contraction of Homoallylic
Ethers to Form Allylic Silanes,” J. Org. Chem. 2009, 74, 7180-7182.
15. L. E. Bourque; P. A. Haile; J. M. N. Loy; K. A. Woerpel, “Silylene oxonium ylides: di- tert-butylsilylene
insertion into C-O bonds,” Tetrahedron 2009, 65, 5608-5613.
14. M. T. Crimmins; J. L. Zuccarello; J. M. Ellis; P. J. McDougall; P. A. Haile; J. D. Parrish; K. A.
Emmitte, “Total Synthesis of Brevetoxin A,” Org. Lett. 2009, 11, 489-482.
13. B. W. Budzik; P. A. Haile; T. V. Hughes; C. A. Sehon; G. Z. Wang, “Spirodihydrobenzofuran
derivatives as chemokine receptor modulators and their preparation, pharmaceutical compositions and use
in the treatment of diseases,” PCT Int. Appl. (2009), WO2009061881.
12. H. S. Eidam; P. A. Haile; T. V. Hughes; C. A. Sehon, “Spiroindolines as modulators of chemokine
receptors,” (2008) US2008142899A.
11. B. W. Budzik; H. S. Eidam; R. M. Fox; K. B. Goodman; D. B. Gotchev; P. A. Haile; T. V. Hughes;
R. Liu; N. A. Miller; T. A. Miskowski; C. A. Sehon; A. Q. Viet; G. Z. Wang; J. Zhang, “Preparation of
spiro-indoline derivatives as chemokine receptor modulators,” PCT Int. Appl. (2008), WO2008157741.
10. K. B. Goodman; C. A. Sehon; P. A. Cleary; J. Philip; S. Peace, “Preparation of pyridinyl sulfonamide
modulators of chemokine receptors, “ PCT Int. Appl. (2007), WO2007067875.
9. C. A. Brooks; P. A. Cleary, K. B. Goodman; S. Peace; J. Philp; C. A. Sehon; C. A. P. Smethurst; S. P.
Watson, “Preparation of azolylmethylbenzenesulfonamides as CCR2 chemokine receptor antagonists, “
PCT Int. Appl. (2007), WO2007014054.
8. P. A. Cleary, K. B. Goodman; S. Peace; C. A. Sehon; J. Philp, “Pyridinyl Sulfonamide Modulators of
Chemokine Receptors, “PCT Int. Appl. (2007), WO2007067875.
7. L. Borque; P. A. Cleary; K. A. Woerpel, “Metal-Catalyzed Silylene Insertions of Allylic Ethers:
Stereoselective Formation of Chiral Allylic Silanes,” J. Am. Chem. Soc. 2007, 129, 12602-12603.
6. D. A. Hales; K. E. Kautzman; N. G. Williams; P. A. Haile; M. P. Barker, “Ion-Molecule Chemistry
within Boron Tribromide Clusters: Experiment and Theory,” J. Phys. Chem. 2007, 111, 2266-2275.
5. M. T. Crimmins; J. L. Zuccarello; P. A. Cleary; J. D. Parrish, “Convergent, Stereoselective Synthesis
of the GHIJ Fragment of Brevetoxin A,” Org. Lett. 2006, 8, 159-162.
4. P. A. Cleary; K. A. Woerpel, “Metal-catalyzed Rearrangement of Homoallylic Ethers to Silylmethyl
Allylic Silanes in the Presence of a Di-t-Butylsilylene Source,” Org. Lett. 2005, 7, 5531-5533.
3. M. T. Crimmins; P. A. Cleary, “Enantioselective Synthesis of the G-Ring of Brevetoxin A,”
Heterocycles 2003, 61, 87-92.
2. T. E. Goodwin; X. Zhou; P. A. Haile; P. Breen; P. J. Anderson; F. C. Hiller; C. M. Compadre,
“Synthesis of 13C, 2H (3)-Salmeterol: An Analytical Internal Standard for Pharmacokinetic Studies,” J. of
Label. Compd. & Radiopharm. 2000, 43, 65-75.
1. D. A. Hales; P. A. Haile; M. P. Barker; H. L. Hunt, “Ion-Molecule Chemistry of BF3 Clusters: Mass
Spectrometric and ab initio Computational Study of BnF3n-1,” J. Phys. Chem. A 1998, 102, 8305-8311.
Presentations

10. P. A. Haile; C. A. Sehon; G. Z. Wang; A. Q. Viet; T. Daniel; K. B. Goodman; D. A. Sha; S. E.
Dowdell; N. Varga; X. Hong; C. Cornejo; A. Olzinski; R. Bernard; C. Evans; A. Emmons; P. Gough; B.
Jacques; C.-w. Chung; Q. Ruben; D. Lee, “Optimization of a biarylsulfonamides series to improve PK
and plasma activity for the CCR2 program,” Presented at the 238th National Meeting of the American
Chemical Society, Washington D.C., August 2009; oral MEDI-453.
9. P. A. Haile; C. A. Sehon; G. Z. Wang; A. Q. Viet; T. Daniel; K. B. Goodman; D. A. Sha; S. E.
Dowdell; N. Varga; X. Hong; C. Cornejo; A. Olzinski; R. Bernard; C. Evans; A. Emmons; P. Gough; B.
Jacques; C.-w. Chung; Q. Ruben; D. Lee, “Optimization of a biarylsulfonamides series to improve PK
and plasma activity for the CCR2 program,” Presented at the 2009 GlaxoSmithKline Chemistry
Conference, Tres Cantos, Spain, May 2009; poster.
8. P. A. Cleary; K. B. Goodman; G. Z. Wang; S. E. Dowdell; D. A. Sha; N. Varga; T. Daniel; A. Q. Viet;
C. A Sehon; “CCR2 Antagonist Program: Sulfonamide Series,” Presented at the GlaxoSmithKline
Chemistry Day, King of Prussia, PA, September 2006.
7. P. A. Cleary and K. A. Woerpel*, “Synthesis and Applications of b-Silylsubstituted Allylic Silanes,”
Presented at the 229th National Meeting of the American Chemical Society, San Diego, CA, March 2005;
paper ORGN 688.
6. P. A. Cleary and K. A. Woerpel*, “Metal-Catalyzed Silylene Transfer to Homoallylic Ethers,”
Presented at the Graduate Student/Postdoctoral Colloquium, University of California-Irvine, April 2005.
5. P. A. Cleary and M. T. Crimmins*, “Studies Directed Toward the Total Synthesis of Brevetoxin A,”
Presented at the Departmental Dissertation Defense, University of North Carolina-Chapel Hill, December
2003.
4. M. T. Crimmins* and P. A. Cleary, “Progress Toward the GHIJ Fragment of Brevetoxin A,” Presented
at the 224th National Meeting of the American Chemical Society, Boston, MA, August 2002; poster
ORGN 802.
3. P. A. Cleary and M. T. Crimmins*, “Studies Directed Toward the Synthesis of Brevetoxin A,”
Presented at the Organic Chemistry Divisional Seminar, University of North Carolina-Chapel Hill,
November 2001.
2. P. A. Haile, M. P. Barker, D. A. Hales*, “Ion-molecule chemistry of boron tribromide in clusters,”
Presented at the 215th National Meeting of the American Chemical Society, Dallas, TX, April 1998;
poster CHED 364.
1. P. A. Haile, M. P. Barker, H. L. Hunt, D. A. Hales*, “Internal energy distributions in (MeOH)nH+ from
a pulsed discharge ion source,” Presented at the 213th National Meeting of the American Chemical
Society, San Francisco, CA, April 1997; poster CHED 478.

HAILE_PAMELA CV 12.15.14

More Related Content

What's hot

Viewers also liked

Similar to HAILE_PAMELA CV 12.15.14

HAILE_PAMELA CV 12.15.14